跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ADYNOVATE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ADYNOVATE
Authorized
STANDARD
ADYNOVATE
takeda canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2c6bf22c6585dd01
Company
takeda canada inc
Type
Standard
Approval Details
Approval Id
2c6bf22c6585dd01
Drug Approval Canada Name
ADYNOVATE
Product Name
ADYNOVATE
Status
Marketed
Status Date
2021-08-27
Original Market Date
2021-08-27
Din
02498596
Drug Class
Human
Dosage Form
Kit , Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
20:28.16
Atc Original
B02BD02 COAGULATION FACTOR VIII
Atc Name
b 02 bd 02
Aig Number
0158550006
Company Name
takeda canada inc
Company Address
3800, 22 Adelaide Street West, Toronto, Ontario, Canada, M5H 4E3
Active Ingredients
ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED
1500 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2c6bf22c6585dd01
Type
Standard
Back to Health Canada Approvals